ADG106 showed no concerning safety signals in the phase 1 trial, and a preliminary result in follicular lymphoma suggests possible clinical activity.
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Preclinical and emerging clinical evidence support the possible use of AMG 510 as a single-agent KRAS (G12C) inhibitor, but preclinical evidence may also support the agent in combination.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
Addition of surgery prior to chemotherapy does not prolong overall survival in recurrent ovarian cancer.
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Patients with advanced non-small cell lung cancer who did not have disease progression after chemoradiotherapy appeared to have a long-term survival benefit with durvalumab.
Next-generation sequencing is being increasingly used to characterize the diversity of T-cell and B-cell receptors in individuals.
Findings seen among postmenopausal breast cancer patients regardless of activity level prediagnosis.
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Patients with NSCLC who did not respond to immune checkpoint blockade had unique molecular characteristics, revealing possible therapeutic targets.
More than 20 percent of those with family history of cancer had childhood asthma.
Risk for subsequent cancer up with development of interim CV events, including heart failure, MI.
In this study, there was no correlation between the presence of MET gene amplification and the presence of MET protein overexpression.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.